DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for acute cystitis — screening already-approved drugs against its 12-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAcute cystitis maps to a 12-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for acute cystitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAB11 family interacting protein 2 (RAB11FIP2) — RAB11FIP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2GZD · 2.44 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
A survey of 161 urologists in Siberia found that 91.9% were familiar with national guidelines for acute uncomplicated cystitis and 95.7% said they adhered to them, but only 47.4% did so almost always. 86.4% started treatment with antimicrobial therapy, choosing fosfomycin in 41.0% of cases, fluoroquinolones in 21.6%, nitrofurans in 20.9%, and cephalosporins in 16.5%. 93.8% believed antibiotic therapy should be accompanied by phytotherapy, and 71.5% prescribed Canephron. The authors concluded that the choice of therapy is not always optimal and that controversies remain.
A 2024 prospective randomised study compared the biologically active complex Cystalis D Plus against fosfomycin trometamol in 120 patients with chronic cystitis at the moment of exacerbation. Patients were divided into four groups: Cystalis D Plus alone, Cystalis D Plus plus NSAIDs, fosfomycin trometamol alone, and fosfomycin trometamol plus NSAIDs. All groups showed a significant decrease in pain intensity on the VAS scale by the third day, a significant reduction in symptoms on the Acute Cystitis Symptom Score scale, a decrease in urine leukocytes, and a decrease in microbial load. The authors stated that all positive changes were comparable between groups and that Cystalis D Plus led to rapid and persistent relief of symptoms both in monotherapy and in combination.
A 2018 review of literature described modern data on diagnosis and treatment of acute cystitis, presenting basic and alternative treatment protocols from the viewpoint of documented medicine, but provided no new patient data.
No evidence from these abstracts supports any claim that any drug or supplement cures acute cystitis. The 2024 study on Cystalis D Plus was small (120 patients), followed patients for only one month, and compared the product to a single antibiotic regimen without a placebo arm. The survey data from 2018 show that even when guidelines exist, compliance is inconsistent. What is still missing are large, placebo-controlled trials with long follow-up, standardised outcome measures, and independent funding.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Urologiia · 2018 · 3 citations
Acute uncomplicated cysititis: do we follow the guidelines?
AbstractINTRODUCTION: Lower urinary tract infection are a common urologic disease, but a therapy is not always optimal. AIM: to evaluate the compliance of prescriptions made by urologists in treatment of patients with lower urinary tract infection, in particular with acute uncomplicated cystitis. MATERIALS AND METHODS: A specially designed questionnaire was filled out by 161 urologists from Novosibirsk, Barnaul and Krasnoyarsk, as well as participants of VII Congress of urologists of Siberia. RESULTS: The survey showed that 34.8%, 27.9%, 22.4% and 14.9% of urologists had 6-10, 11-20, 1-5 and more than 20 patients with acute uncomplicated cystitis a month, respectively. According to results, 91.9% of urologists are familiar to National guidelines on treatment of lower urinary tract infections and 91.2% of doctors consider them to be reasonable. Among those surveyed, 29.2% of urologists believe that National Guidelines differ from European Guidelines; 95.7% of participants adhere to recommendations, but only 47.4% respect it almost always, 16.9% do it in half of cases and the remaining 35.7% comply with them in less than 40% cases. Moreover, 86.4% of urologists started a treatment of acute cystitis with antimicrobial therapy and preferred fosfomycin in 41.0%, nitrofurans in 20.9%, fluoroquinolones in 21.6% and cephalosporins in 16.5% cases, respectively. Almost all respondents (93.8%) are convinced that antibiotic therapy should be accompanied by phytotherapy, and 71.5% of urologists administer Canephron. CONCLUSION: In the urologic community there are controversies in the treatment of patients with acute uncomplicated cystitis. The choice of therapy is not always optimal.
Meditsinskiy sovet = Medical Council · 2018 · 1 citations · open access
Acute cystitis in the practice of an obstetrician-gynecologist
AbstractThis review of literature discusses modern data on the diagnosis and treatment of the acute cystitis. Epidemiology and etiology of acute cystitis are described. The basic and alternative treatment protocols for the acute cystitis are presented from the documented medicine viewpoint.
Experimental and Сlinical Urology · 2024 · 0 citations · open access
The search for alternative therapy for chronic cystitis: results of a prospective comparative randomized study on the effectiveness of a biologically active complex «Cystalis® D Plus».
AbstractIntroduction. Cystitis is one of the most prevalent urinary tract infection (UTI) type. An important specifity of cystitis is the tendency to relapse and chronization of the disease. The search for a safe and effective strategy for the treatment and prevention of recurrence of chronic cystitis is an extremely urgent problem. The purpose of this study is to compare the effectiveness of Cystalis® D Plus with antibiotics treatment in chronic cystitis relapses treatment. Materials and methods. The study included 120 patients with an established diagnosis of chronic cystitis at the moment of intensification. All patients were randomized into 4 groups: the first group received Cystalis® D Plus in monotherapy for 7 days, the second group received Cystalis® D Plus for 7 days together with nonsteroidal anti-inflammatory drugs (NSAIDs) in accordance with the recommendations, the third group received fosfomycin trometamol in accordance with the recommendations, the fourth group received fosfomycin trometamol together with NSAIDs in accordance with recommendations. All groups were monitored for a month after the start of therapy. Results. Patients from all groups noted a significant decrease in intensity of pain according to VAS already on the third day of treatment. Also, there was a significant decrease in the symptoms of acute cystitis on thescale «Acute cystitis symptom score» (ACSS scale), a decrease in the number of leukocytes in the urine and a decrease in microbial load in all groups. All the positive changes in the groups were comparable to each other. Conclusions. «Cystalis® D Plus» leads to rapid and persistent relief of symptoms of recurrent cystitis both in monotherapy mode and in combination with other groups of drugs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
